---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-006498"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T04:47:39.787299+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Trevi's Haduvio meets Phase 2 CANAL primary endpoint; 52% placebo-adjusted cough reduction in IPF patients

## Summary
- Interim analysis (N=26) showed 52% placebo-adjusted reduction in daytime cough frequency (p<0.0001); 100% probability of success.
- Company stops further recruitment into CANAL trial based on strong and consistent interim data.
- Haduvio well tolerated; no new safety signals; one unrelated SAE reported.
- Full CANAL trial data expected early Q3 2022, with approximately 40 total subjects.

## SEC filing metadata
- accession: 0001564590-22-006498
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000156459022006498/0001564590-22-006498-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000156459022006498/trvi-8k_20220224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-006498
- JSON: https://secwatch.observer/filing/0001564590-22-006498.json
- Plain text: https://secwatch.observer/filing/0001564590-22-006498.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.